Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2022-08-08 Declaration of Voting R…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release dated August 8, 2022, titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 1ER AOUT 2022" (New number of shares and voting rights of Innate Pharma as of August 1, 2022). It explicitly states it is published in accordance with French Commercial Code articles and AMF regulations, detailing the total number of shares and voting rights as of a specific date. This content directly relates to changes in the company's capital structure and shareholder rights reporting, which aligns best with the 'Share Issue/Capital Change' (SHA) definition, as it reports the current count of shares and voting rights, which is a fundamental aspect of capital structure reporting. Although it involves voting rights, it is a factual update on the share count, not the results of a vote (DVA) or a proxy solicitation (PSI). It is not a general earnings release (ER) or a comprehensive quarterly report (IR).
2022-08-08 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose: to release the 'Total number of shares outstanding as well as its voting rights as at August 1, 2022,' citing compliance with the French 'Code de Commerce' and AMF regulations. This type of mandatory disclosure regarding the total share count and voting rights is a specific regulatory filing requirement, often related to major shareholding thresholds or capital structure transparency. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It most closely aligns with a mandatory regulatory disclosure concerning share capital structure and ownership transparency, which falls under the general category of Regulatory Filings (RNS) or potentially a specific notification related to share capital changes, though RNS is the best fit for mandatory, non-standardized regulatory updates like this one concerning voting rights calculations.
2022-08-08 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2022-08-01 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces a specific corporate event: the discontinuation of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca based on a futility interim analysis. This type of announcement, which communicates key operational and clinical trial updates outside of a formal periodic report (like 10-K or IR), is best classified as an Earnings Release (ER) if it contains financial highlights, or more generally, a Regulatory Filing (RNS) if it's a broad operational update. Since it discusses clinical trial outcomes, management commentary, and partnership details, it functions as a material event disclosure. Given the options, and recognizing that this is a time-sensitive announcement of a major development (clinical trial failure/discontinuation) often released concurrently with or instead of a formal earnings report, 'ER' (Earnings Release) is often used for such material operational news releases, although 'RNS' (Regulatory Filings) is a strong fallback. However, because it is a press release detailing significant operational news (clinical trial update) and includes quotes from the CEO, it aligns closely with the function of an Earnings Release, which often bundles operational updates with financial context, even if specific quarterly numbers aren't the focus. Since it is not a full report (10-K, IR) and is a formal announcement, ER is the most fitting category for a material operational update press release. FY 2022
2022-08-01 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated August 1, 2022, announcing that the Phase 3 INTERLINK-1 clinical study for monalizumab, conducted by AstraZeneca, did not meet its efficacy threshold and will be discontinued based on the IDMC recommendation. This is a specific operational update regarding a clinical trial and drug development program, not a full financial report (like 10-K or IR), an earnings release (ER), or a formal regulatory filing announcement (RPA/RNS) about a mandatory filing. It details scientific progress, partnership terms, and future development focus (PACIFIC-9, NeoCOAST-2). This type of announcement, focusing on clinical trial results and strategic pipeline updates, is best classified as an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed nature of the scientific and partnership information provided, it functions as a key update for investors, aligning closely with the purpose of an Investor Presentation (IP), although it is structured as a press release. However, since it is a direct announcement of a major clinical trial outcome and strategic direction, and does not fit perfectly into the other specific categories (like DIV, DIRS, MANG), it falls under the broader category of investor-focused material. Since 'IP' covers detailed presentations on strategy and financials, and this is a detailed strategic update on a key asset, IP is a strong candidate. If it were purely a brief regulatory notice, RNS would apply. Given the depth of the scientific and financial partnership details, I will classify it as an Investor Presentation (IP).
2022-08-01 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2022-07-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.